O7.5. LONG-TERM SAFETY AND TOLERABILITY OF BREXPIPRAZOLE IN PATIENTS WITH SCHIZOPHRENIA

Por Hakala, Mika, Gislum, Mette, Skuban, Aleksandar, Meehan, Stine
Publicado no Schizophr Bull (2018)

PS155. Long-term safety of adjunctive brexpiprazole (OPC-34712) in MDD: results from two 52-week open-label studies

Por Nelson, Craig, Skuban, Aleksandar, Zhang, Peter, Weiller, Emmanuelle, Weiss, Catherine
Publicado no Int J Neuropsychopharmacol (2016)

PM385. Long-term safety of brexpiprazole (OPC-34712) in schizophrenia: results from two 52-week open-label studies

Por Correll, Christoph U., Skuban, Aleksandar, Ouyang, John, Weiller, Emmanuelle, Weiss, Catherine
Publicado no Int J Neuropsychopharmacol (2016)

PS152. Efficacy and safety of brexpiprazole (OPC-34712) as adjunctive treatment in major depressive disorder: Meta-analysis of two pivotal studies

Por Eriksson, Hans, Weiller, Emmanuelle, Weiss, Catherine, Zhang, Peter, Skuban, Aleksandar, Thase, Michael E.
Publicado no Int J Neuropsychopharmacol (2016)

PM421. Efficacy and safety of brexpiprazole (OPC-34712) in acute schizophrenia: a pooled analysis of two pivotal studies

Por Skuban, Aleksandar, Kane, John M., Ouyang, John, Weiss, Catherine, Weiller, Emmanuelle, Correll, Christoph U.
Publicado no Int J Neuropsychopharmacol (2016)

A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder

Por Hobart, Mary, Zhang, Peter, Skuban, Aleksandar, Brewer, Claudette, Hefting, Nanco, Sanchez, Raymond, McQuade, Robert D.
Publicado no J Clin Psychopharmacol (2019)